article thumbnail

The Definition of “Fully Vaccinated” Needs to Change

Eye on FDA

We are long gone from the days of being threatened by a rampant Alpha virus to having several successive variants. We now have multiple vaccines – mRNA and traditional in the U.S. However there is also an alarming rise among people who have completed their primary vaccination. and an even greater array outside the U.S.

Vaccine 72
article thumbnail

Covid researchers launch Monkeypox study  

Drug Discovery World

It will also assess the time taken until throat and lesion swabs test negative for monkeypox virus and the proportion of patients who require hospitalisation due to complications from the disease. . Tecovirimat prevents the Monkeypox virus from leaving infected cells, helping stop its spread within the body.

Research 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Where is the Ignite Theater tech leading us?

Drug Discovery World

Masaru Kanekiyo , Chief of Molecular Immunoengineering Section (MIS) of the Vaccine Research Center (VRC) at the US National Institute of Allergy and Infectious Diseases (NIAID), will present ‘Structural vaccinology for influenza’.

article thumbnail

Join DDW for the SLAS2024 Ignite Theater ‘Innovation from lab to patient’

Drug Discovery World

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Vaccine 130
article thumbnail

AstraZeneca’s COVID-19 Vaccine Boasts Strong Results with Up to 90% Efficacy

The Pharma Data

As the Pfizer and BioNTech COVID-19 vaccine goes to regulators and the Moderna vaccine approaches the end of its Phase III trials, AstraZeneca and the University of Oxford announced high-level results from an interim analysis of their COVID-19 vaccine, AZD1222. The combined analysis showed average efficacy of 70%.

Vaccine 52
article thumbnail

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people

The Pharma Data

Safety profiles of Vaxzevria, and the mRNA-based vaccine were similar and overall favourable. Very rare clotting disorders (TTS) were observed with both vaccines but these were in line with what would be expected in the general population and lower than in those diagnosed with COVID-19.

Vaccine 52
article thumbnail

Health Officials Work to Speed Up U.S. COVID Vaccine Rollout

The Pharma Data

health officials raced to ramp up the delivery of COVID-19 vaccines across the country as both coronavirus case counts and death tallies continued to hit record highs. “We really need to get this vaccine out more quickly, because this is really our only tool,” Dr. Scott Gottlieb, former commissioner of the U.S. .

Vaccine 52